The Premier Consulting Blog

APRIL 13, 2025

On April 10, 2025, the US FDA announced that it has a long-term plan to eliminate conventional animal testing in drug development, starting with monoclonal antibodies (mAbs).[ from approved products in other countries) to inform doses and development. 7] This was a landmark change in philosophy.

Animal Testing 52

Animal Testing FDA Drug Development Production 52

Drug Target Review

JULY 3, 2025

It is becoming increasingly evident that generative artificial intelligence (GenAI) is a resourceful tool for helping pharmaceutical companies reduce manual tasks required by clinical trials. Long-term sustainability may benefit from identifying priority indications, exploring emerging mechanisms of action and refining development priorities.

Drug Development 65

Drug Development Drugs Animal Testing Engineering 65

Drug Target Review

JULY 7, 2025

Non-human primates (NHPs), such as macaques and cynomolgus monkeys, have long served as a cornerstone in preclinical drug development due to their close genetic, anatomical and physiological resemblance to humans. Food and Drug Administration (FDA). Trends in Non-Human Primate Use for Research and Testing.

Drug Research 52

Drug Research Research Animal Testing Drugs 52

Drug Target Review

SEPTEMBER 19, 2023

puts an end to the previous mandate that all drugs need to be tested on animals prior to human clinical trials. Prior to this European Union Parliament, in 2021, voted for animal testing phase out. The US FDA Modernisation Act 2.0., These guidelines drive the legitimacy of the models towards regulatory approval.

Animal Testing 98

Animal Testing Clinical Trials Pharmaceutical Companies FDA 98

Vial

MAY 20, 2024

Clinical CROs in Clinical Research Randomized clinical trials are the gold-standard of evidence-based medicine, representing the culmination of the long, arduous drug development pipeline. The two broadest categories of drug development can be separated into the preclinical and clinical research stages. over this period.

Clinical Research 52

Clinical Research Clinical Trials Research Trials 52

Drug Target Review

SEPTEMBER 26, 2023

CNS-related issues account for nearly a quarter of failures during clinical development, a phase where consequences are high in terms of resources and patient impact. CNS-related issues account for nearly a quarter of failures during clinical development, a phase where consequences are high in terms of resources and patient impact.

Drugs 112

Drugs FDA Disease Animal Testing 112

The Pharma Data

JANUARY 11, 2021

The publication substantiates the Company’s position as a leader in the field with reliable and robust cutting-edge technology, ready for widespread adoption across the pharmaceutical industry. ‘Impact of organ-on-a-chip technology on pharmaceutical R&D costs’ [link]. View source version on businesswire.com: [link].

FDA 40

FDA Animal Testing Clinical Trials Pharmaceuticals 40